title: Thalidomide in combination with dexamethasone-induced rhabdomyolysis in a patient with refractory myeloma.
authors.forename: Can
authors.initials: C
authors.lastname: Boga
authors.forename: Hakan
authors.initials: H
authors.lastname: Ozdogu
authors.forename: Mahmut
authors.initials: M
authors.lastname: Yeral
authors.forename: Ebru
authors.initials: E
authors.lastname: Kizilkilic
authors.forename: Lulufer
authors.initials: L
authors.lastname: Tamer
mesh_terms: D018931:Antineoplastic Agents, Hormonal / Q000009:adverse effects*; D003907:Dexamethasone / Q000009:adverse effects*; D004359:Drug Therapy, Combination; D006801:Humans; D007070:Immunoglobulin A / Q000097:blood; D007166:Immunosuppressive Agents; D008297:Male; D008875:Middle Aged; D009101:Multiple Myeloma / Q000188:drug therapy*; D009212:Myoglobinuria / Q000097:blood / Q000139:chemically induced; D012206:Rhabdomyolysis / Q000139:chemically induced*; D016879:Salvage Therapy; D013792:Thalidomide / Q000009:adverse effects*; D016896:Treatment Outcome
chemical_list: D018931:Antineoplastic Agents, Hormonal; D007070:Immunoglobulin A; D007166:Immunosuppressive Agents; D013792:Thalidomide; D003907:Dexamethasone